With a lack of historical population-based information to steer COVID-19 research, pharmaceutical companies are struggling to understand the everchanging virus as they work tirelessly to develop a vaccine in less than one year. Research teams can access near real-time COVID-19 patient data with Touchstone® for COVID-19 National Data Sets and Registry from over 80 million patients across the United States and three national data sources: John Hopkins University, The New York Times, and The COVID Tracking Project.
The Registry offers up-to-date, comprehensive data with outcome analysis and clinical trial analysis so research teams can stay up to date through every stage of the vaccine development process.